Novo Nordisk said that if approved for use ... and showed that it was equivalent to insulin glargine, another once-daily basal insulin, in glucose-lowering efficacy with a similar safety profile.

T he US Food and Drug Administration (FDA) and pharmaceutical company Novo Nordisk are now in an attempt to making more ...

Danish company Novo Nordisk have announced positive results ... Compared to once-daily basal insulin (insulin degludec or insulin glargine U100/U300) analogues, the 52-week ONWARDS 5 trial ...

A U.S. federal court has approved a settlement between Novo Nordisk (NVO) and Minnesota ending a longstanding litigation that accused three leading insulin manufacturers of charging excessive ...

PITTSBURGH (CN) — Bashing a Biden-era law that gives Medicare the power to directly negotiate the price of certain high-cost prescription drugs, an attorney for the pharmaceutical giant Novo Nordisk ...

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results but remains strong in diabetes treatment, insulin, and GLP-1 products. I outline the bull case ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO) built its business on insulin and has emerged as a leading innovator in GLP-1 agonists, relatively new drugs that treat obesity and type 2 diabetes by ...

As a pioneer in diabetes care, Novo Nordisk NVO claims 34% of the USD 80 billion-plus diabetes treatment market and roughly half of the insulin market, itself worth more than USD 15 billion.

Novo Nordisk has invested 6.4bn Brazilian reais ... Located in Southeastern Brazil, the Montes Claros site is already the largest insulin factory in Latin America. A variety of products will ...